ArticleJournal of cardiothoracic surgery2026
Identification and analysis of EphrinB2/EphB4 signaling pathway and angiogenesis related biomarkers in coronary artery disease based on bioinformatics.
Article in Journal of cardiothoracic surgery, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundEphrinB2 and its receptor EphB4 have been reported to play a crucial role in the development of the cardiovascular system, and the process of coronary artery disease (CAD) is closely related to angiogenesis. The aim of this study is to identify and analyze the therapeutic value of the EphrinB2/EphB4 signaling pathway and angiogenesis-related biomarkers.
methodsThe CAD chip data (GSE42148) was used for differential analysis to identify differently expressed genes (DEGs). Key module genes associated with CAD were identified using WGCNA. Machine learning and expression validation were executed for screening biomarkers. In addition, the biological functions of biomarkers were explored using enrichment analyses. Finally, the diagnostic and therapeutic value of biomarkers was explored through immune infiltration analysis and drug prediction.
resultsTotally, 927 DEGs were identified in CAD and control groups. A total of 1,605 key CAD-related module genes were obtained for subsequent analyses. Then, PTX3, DLL4, and CITED4 were identified as biomarkers. Enrichment analysis suggested that three biomarkers were associated with allograft rejection. Analysis of 28 immune cell infiltrates revealed that CD56dim natural killer cell, eosinophil, mast cell, and MDSC etc. were significantly different between CAD and control groups. Finally, small-molecule drugs, notably simvastatin and calcitriol, were predicted and validated via molecular docking (binding energies < -6.0 kcal/mol) to have a potential therapeutic role in CAD by targeting PTX3 and CITED4, respectively.
conclusionWe obtained three EphrinB2/EphB4 signaling pathway and angiogenesis-related biomarkers (PTX3, DLL4, and CITED4) linked with CAD, which provide new references for the treatment of CAD.
Indexed as
Identifiers
42477815What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.